SARVARI YELLAPRAGADA to Humans
This is a "connection" page, showing publications SARVARI YELLAPRAGADA has written about Humans.
Connection Strength
0.145
-
Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge? JAMA Oncol. 2021 10 01; 7(10):1449-1450.
Score: 0.021
-
Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv. 2020 04 28; 4(8):1643-1646.
Score: 0.019
-
HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):e143-e146.
Score: 0.016
-
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clin Lymphoma Myeloma Leuk. 2024 08; 24(8):523-530.
Score: 0.006
-
Dyspneic and pink. J Hosp Med. 2024 Jul; 19(7):623-628.
Score: 0.006
-
Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer. Sci Rep. 2024 01 31; 14(1):2612.
Score: 0.006
-
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284.
Score: 0.006
-
Veterans with blood cancers: Clinical trial navigation and the challenge of rurality. J Rural Health. 2024 01; 40(1):114-120.
Score: 0.006
-
Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. Cancer Res Commun. 2022 12; 2(12):1693-1710.
Score: 0.006
-
Disparities in mortality among acute myeloid leukemia-related hospitalizations. Cancer Med. 2023 02; 12(3):3387-3394.
Score: 0.006
-
Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021 09 28; 5(18):3511-3514.
Score: 0.005
-
Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093.
Score: 0.005
-
The detrimental association between fear of falling and motor performance in older cancer patients with chemotherapy-induced peripheral neuropathy. Gait Posture. 2021 07; 88:161-166.
Score: 0.005
-
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019 06 13; 133(24):2615-2618.
Score: 0.004
-
Using wearables to screen motor performance deterioration because of cancer and chemotherapy-induced peripheral neuropathy (CIPN) in adults - Toward an early diagnosis of CIPN. J Geriatr Oncol. 2019 11; 10(6):960-967.
Score: 0.004
-
Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother. 2018 Oct; 41(8):379-383.
Score: 0.004
-
Significant improvement in overall survival among patients diagnosed with low-risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors. Br J Haematol. 2017 04; 177(1):142-144.
Score: 0.004
-
State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias. Radiol Clin North Am. 2016 May; 54(3):581-96.
Score: 0.004
-
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43.
Score: 0.003
-
Case report: isolated cardiac amyloidosis: an enigma unravelled. Methodist Debakey Cardiovasc J. 2015 Jan-Mar; 11(1):53-8.
Score: 0.003
-
Hypomethylating agents for urologic cancers. Future Oncol. 2011 Mar; 7(3):447-63.
Score: 0.003
-
Lactadherin mediates sickle cell adhesion to vascular endothelial cells in flowing blood. Haematologica. 2007 Sep; 92(9):1266-7.
Score: 0.002